CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 39 target
Drug / intervention
Lidocainedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01314300
NCT01314300Phase 2Completed
CompareCT.gov

VERSATIS - Efficacy and Safety of Lidocaine 5% Plasters (Versatis® 5%) in Child, Adolescents and Young Adults With Neuropathic Pains or Vasoocclusive Sickle Cell Crisis Pains

Centre Leon Berard·interventional·Posted Mar 14, 2011·Updated Oct 30, 2014

In Brief

A Phase 2 clinical trial evaluating Lidocaine for Neuropathic Pains and Vasoocclusive Sickle Cell Crises Pains. Completed, enrolled 39 participants across 2 sites.

Detailed Summary

Lidocaine 5% plaster (VERSATIS® 5%) showed its efficacy and safety in the post-herpetic zoster adult pains. This treatment is recommended in first intention in adult neuropathic pains with allodynia. The purpose of this study is to assess efficacy and safety of lidocaine 5% plaster (VERSATIS® 5%) in the pediatric neuropathic pains and vasoocclusive sickle cell crises pains.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuropathic Pains, Vasoocclusive Sickle Cell Crises Pains
CountriesFrance
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 14, 2011
Enrollment StartMar 1, 2011
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.3 years ago

Interventions

Lidocainedrug

Lidocaine 5% plaster